Strain Name:

FVB-Tg(tetO-MAPT*P301L)#Kha/JlwsJ

Stock Number:

015815

Order this mouse

Availability:

Repository- Live

Use Restrictions Apply, see Terms of Use
These tetO-MAPT*P301L (or rTg4510) transgenic mice express in the brain the human P301L mutant of the four-repeat microtubule-associated protein tau (MAPT) gene under the control of a tetracycline-responsive (TRE or tetO) promoter. They may be useful in generating bi-transgenic mice for the inducible regulation of expression for studying the formation of neurofibrillary tangles associated with the progression of Alzheimer's disease.

Description

Strain Information

Former Names FVB-Tg(tetO-MAPT*P301L)#Kha/J    (Changed: 05-JUN-12 )
Type Coisogenic; Mutant Strain; Transgenic;
Additional information on Genetically Engineered and Mutant Mice.
Visit our online Nomenclature tutorial.
Mating SystemNoncarrier x Hemizygote         (Female x Male)   20-OCT-11
Mating SystemHemizygote x Noncarrier         (Female x Male)   20-OCT-11
Specieslaboratory mouse
Generation?pN1+N1F2 (11-DEC-13)
Generation Definitions
 
Donating InvestigatorDr. Karen K. Hsiao Ashe,   University of Minnesota
Donating InvestigatorDr. Jada Lewis,   Center for Translational Research in Neurodegenerative Disease
Donating InvestigatorDr. Michael Hutton,   Mayo Clinic

Description
The tetO-MAPT*P301L transgene contains a tetracycline operator (tetO) driving expression of the human four-repeat microtubule-associated protein tau (MAPT) gene. The transgene also contains the frontotemporal dementia-associated P301L mutation sequences (tauP310L) and untranslated sequence from the mouse prion protein gene (Prnp) driving transgene expression in the brain. Homozygous mice are not viable. When mated to a mutant strain expressing reverse tetracycline-controlled transactivator protein (rtTA) or tetracycline-controlled transactivator protein (tTA), expression of tauP301L protein may be regulated with the tetracycline analog doxycycline (dox) in the double mutant offspring.

When bred to mice expressing tTa under regulatory control of the forebrain-specific calcium-calmodulin-dependent kinase II (Camk2a) promoter (see Stock No. 003010), bitransgenic mice expressing approximately 13 units of transgene exhibit age-independent behavioral and pathological abnormalities, as well as age-dependent functional and structural abnormalities, associated with the progression of Alzheimer's disease. After treatment with dox, neuronal death ceases and the ability to acquire and retain new spatial memories is restored.

Development
The tetO-MAPT*P301L transgene was designed with the human four-repeat microtubule-associated protein tau (MAPT), lacking the amino terminal sequence (4R0N) and containing the frontotemporal dementia-associated P301L mutation sequences. Expression of this tauP310L gene was driven by a tetracycline operator (tetO) upstream of a cytomegalovirus minimal promoter, and contained exons 2-3 of the mouse prion protein gene (prnp) untranslated sequence. This transgene was microinjected into fertilized FVB/NCrl oocytes. The resulting mice were bred with FVB/NCrl mice to establish the colony. Upon arrival, transgenic mice were bred with FVB/NJ inbred mice (Stock No. 001800) for at least one generation to establish this colony.

Control Information

  Control
   Noncarrier
   001800 FVB/NJ
 
  Considerations for Choosing Controls

Related Strains

Alzheimer's Disease Models
005987   129-Achetm1Loc/J
006409   129S1.129(Cg)-Tg(APPSw)40Btla/Mmjax
008077   129S1/Sv-Bchetm1Loc/J
016198   129S6.Cg-Tg(Camk2a-tTA)1Mmay/JlwsJ
014556   129S6/SvEv-Apoetm4Mae/J
006555   A.129(B6)-Tg(APPSw)40Btla/Mmjax
005708   B6.129-Apbb1tm1Quhu/J
004714   B6.129-Bace1tm1Pcw/J
004098   B6.129-Klc1tm1Gsn/J
004193   B6.129-Psen1tm1Mpm/J
003615   B6.129-Psen1tm1Shn/J
005300   B6.129-Tg(APPSw)40Btla/Mmjax
005617   B6.129P-Psen2tm1Bdes/J
002609   B6.129P2-Nos2tm1Lau/J
007685   B6.129P2-Psen1tm1Vln/J
007999   B6.129P2-Sorl1Gt(Ex255)Byg/J
008087   B6.129S1-Bchetm1Loc/J
002509   B6.129S2-Plautm1Mlg/J
005301   B6.129S2-Tg(APP)8.9Btla/J
004163   B6.129S4-Cdk5r1tm1Lht/J
010959   B6.129S4-Grk5tm1Rjl/J
010960   B6.129S4-Grk5tm2Rjl/J
002213   B6.129S4-Ngfrtm1Jae/J
006406   B6.129S4-Tg(APPSwLon)96Btla/Mmjax
006469   B6.129S4-Tg(PSEN1H163R)G9Btla/J
012564   B6.129S5-Dhcr24tm1Lex/SbpaJ
004142   B6.129S7-Aplp2tm1Dbo/J
004133   B6.129S7-Apptm1Dbo/J
007251   B6.129X1-Mapttm1Hnd/J
013040   B6.Cg-Apoetm1Unc Ins2Akita/J
005642   B6.Cg-Clutm1Jakh/J
005491   B6.Cg-Mapttm1(EGFP)Klt Tg(MAPT)8cPdav/J
009126   B6.Cg-Nos2tm1Lau Tg(Thy1-APPSwDutIowa)BWevn/Mmjax
005866   B6.Cg-Tg(APP695)3Dbo Tg(PSEN1dE9)S9Dbo/Mmjax
008730   B6.Cg-Tg(APPSwFlLon,PSEN1*M146L*L286V)6799Vas/Mmjax
005864   B6.Cg-Tg(APPswe,PSEN1dE9)85Dbo/Mmjax
007575   B6.Cg-Tg(CAG-Ngb,-EGFP)1Dgrn/J
016197   B6.Cg-Tg(CAG-OTC/CAT)4033Prab/J
005855   B6.Cg-Tg(Camk2a-Prkaca)426Tabe/J
007004   B6.Cg-Tg(Camk2a-tTA)1Mmay/DboJ
004996   B6.Cg-Tg(DBH-Gal)1923Stei/J
007673   B6.Cg-Tg(Gad1-EGFP)3Gfng/J
004662   B6.Cg-Tg(PDGFB-APP)5Lms/J
006293   B6.Cg-Tg(PDGFB-APPSwInd)20Lms/2Mmjax
006006   B6.Cg-Tg(Prnp-APP)A-2Dbo/J
008596   B6.Cg-Tg(Prnp-Abca1)EHol/J
006005   B6.Cg-Tg(Prnp-App/APPswe)E1-2Dbo/Mmjax
007180   B6.Cg-Tg(Prnp-ITM2B/APP695*40)1Emcg/J
007182   B6.Cg-Tg(Prnp-ITM2B/APP695*42)A12Emcg/J
005999   B6.Cg-Tg(SBE/TK-luc)7Twc/J
012597   B6.Cg-Tg(Thy1-COL25A1)861Yfu/J
007051   B6.Cg-Tg(tetO-APPSwInd)102Dbo/Mmjax
007052   B6.Cg-Tg(tetO-APPSwInd)107Dbo/Mmjax
007049   B6.Cg-Tg(tetO-APPSwInd)885Dbo/Mmjax
009337   B6.FVB-Tg(Prnp-RTN3)2Yanr/J
006394   B6;129-Apba2tm1Sud Apba3tm1Sud Apba1tm1Sud/J
008364   B6;129-Chattm1(cre/ERT)Nat/J
008476   B6;129-Ncstntm1Sud/J
004807   B6;129-Psen1tm1Mpm Tg(APPSwe,tauP301L)1Lfa/Mmjax
007605   B6;129P-Psen1tm1Vln/J
005618   B6;129P2-Bace2tm1Bdes/J
008333   B6;129P2-Dldtm1Ptl/J
002596   B6;129P2-Nos2tm1Lau/J
003822   B6;129S-Psen1tm1Shn/J
012639   B6;129S4-Mapttm3(HDAC2)Jae/J
012869   B6;129S6-Apbb2tm1Her/J
006410   B6;129S6-Chattm2(cre)Lowl/J
005993   B6;129S6-Pcsk9tm1Jdh/J
008636   B6;C-Tg(Prnp-APP695*/EYFP)49Gsn/J
007002   B6;C3-Tg(Prnp-ITM2B/APP695*42)A12Emcg/Mmjax
008169   B6;C3-Tg(Prnp-MAPT*P301S)PS19Vle/J
000231   B6;C3Fe a/a-Csf1op/J
008850   B6;SJL-Tg(Mt1-LDLR)93-4Reh/AgnJ
003378   B6C3-Tg(APP695)3Dbo Tg(PSEN1)5Dbo/J
004462   B6C3-Tg(APPswe,PSEN1dE9)85Dbo/Mmjax
003741   B6D2-Tg(Prnp-MAPT)43Vle/J
016556   B6N.129-Ptpn5tm1Pjlo/J
018957   B6N.129S6(B6)-Chattm2(cre)Lowl/J
024841   B6N.Cg-Tg(Prnp-MAPT*P301S)PS19Vle/J
006554   B6SJL-Tg(APPSwFlLon,PSEN1*M146L*L286V)6799Vas/Mmjax
012621   C.129S(B6)-Chrna3tm1.1Hwrt/J
002328   C.129S2-Plautm1Mlg/J
003375   C3B6-Tg(APP695)3Dbo/Mmjax
005087   C57BL/6-Tg(Camk2a-IDE)1Selk/J
005086   C57BL/6-Tg(Camk2a-MME)3Selk/J
008833   C57BL/6-Tg(Camk2a-UBB)3413-1Fwvl/J
007027   C57BL/6-Tg(Thy1-APPSwDutIowa)BWevn/Mmjax
010800   C57BL/6-Tg(Thy1-PTGS2)300Kand/J
010703   C57BL/6-Tg(Thy1-PTGS2)303Kand/J
005706   C57BL/6-Tg(tetO-CDK5R1/GFP)337Lht/J
006618   C57BL/6-Tg(tetO-COX8A/EYFP)1Ksn/J
007677   CB6-Tg(Gad1-EGFP)G42Zjh/J
007072   CByJ.129P2(B6)-Nos2tm1Lau/J
006472   D2.129(B6)-Tg(APPSw)40Btla/Mmjax
007067   D2.129P2(B6)-Apoetm1Unc/J
013719   D2.Cg-Apoetm1Unc Ins2Akita/J
003718   FVB-Tg(GadGFP)45704Swn/J
013732   FVB-Tg(NPEPPS)1Skar/J
013156   FVB-Tg(tetO-CDK5R1*)1Vln/J
002329   FVB.129S2-Plautm1Mlg/J
003753   FVB/N-Tg(Eno2CDK5R1)1Jdm/J
006143   FVB/N-Tg(Thy1-cre)1Vln/J
008051   NOD.129P2(B6)-Ctsbtm1Jde/RclJ
008390   STOCK Apptm1Sud/J
012640   STOCK Hdac2tm1.2Rdp/J
004808   STOCK Mapttm1(EGFP)Klt Tg(MAPT)8cPdav/J
004779   STOCK Mapttm1(EGFP)Klt/J
014092   STOCK Tg(ACTB-tTA2,-MAPT/lacZ)1Luo/J
014544   STOCK Tg(tetO-ABL1*P242E*P249E)CPdav/J
View Alzheimer's Disease Models     (109 strains)

Strains carrying   Tg(tetO-MAPT*P301L)#Kha allele
024854   STOCK Tg(Camk2a-tTA)1Mmay Tg(tetO-MAPT*P301L)#Kha/J
View Strains carrying   Tg(tetO-MAPT*P301L)#Kha     (1 strain)

View Strains carrying other alleles of MAPT     (17 strains)

Strains carrying other alleles of tetO
008079   129S-Ppargtm2Yba/J
016178   B6(Cg)-Tg(tetO-Cry2)3Jt/J
016176   B6(Cg)-Tg(tetO-Per2)2Jt/J
023757   B6(Cg)-Tg(tetO-tetX,lacZ)1Gogo/UmriJ
009602   B6.129S4(Cg)-Kcnn2tm2Jpad/J
009603   B6.129S4-Kcnn3tm1Jpad/J
023910   B6.Cg-Col1a1tm1(tetO-Lin28a)Gqda/J
023911   B6.Cg-Col1a1tm2(tetO-LIN28B)Gqda/J
023912   B6.Cg-Col1a1tm3(tetO-Mirlet7g/Mir21)Gqda/J
017983   B6.Cg-Col1a1tm9(tetO-Dnmt3b_i1)Jae Gt(ROSA)26Sortm1(rtTA*M2)Jae/J
014588   B6.Cg-Gt(ROSA)26Sortm1(rtTA*M2)Jae Col1a1tm6(tetO-MSI2)Jae/J
023749   B6.Cg-Gt(ROSA)26Sortm1(rtTA*M2)Jae Tg(tetO-Pou5f1,-Sox2,-Klf4,-Myc)1Srn/J
014648   B6.Cg-Gt(ROSA)26Sortm37(H1/tetO-RNAi:Taz)Arte/ZkhuJ
006361   B6.Cg-Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/J
016998   B6.Cg-Tg(TetO-Axin1,EGFP)TA6Cos/J
003762   B6.Cg-Tg(tetFosb)4468Nes/J
007051   B6.Cg-Tg(tetO-APPSwInd)102Dbo/Mmjax
007052   B6.Cg-Tg(tetO-APPSwInd)107Dbo/Mmjax
007049   B6.Cg-Tg(tetO-APPSwInd)885Dbo/Mmjax
007618   B6.Cg-Tg(tetO-Arntl)1Jt/J
017555   B6.Cg-Tg(tetO-CALY)5Cber/J
024114   B6.Cg-Tg(tetO-CHRM4*)2Blr/J
008277   B6.Cg-Tg(tetO-Clockm1Jt)CL57Jt/J
008468   B6.Cg-Tg(tetO-DTA)1Gfi/J
017791   B6.Cg-Tg(tetO-Hamp)2181Nca/J
009344   B6.Cg-Tg(tetO-Ifng)184Pop/J
009136   B6.Cg-Tg(tetO-Kcnj2,lacZ)1Gogo/J
013583   B6.Cg-Tg(tetO-LRRK2)C7874Cai/J
020652   B6.Cg-Tg(tetO-Mif)279Aren/J
017331   B6.Cg-Tg(tetO-Ppp3ca*)11255Kndl/J
017332   B6.Cg-Tg(tetO-Ppp3ca*)13967Kndl/J
017330   B6.Cg-Tg(tetO-TAg*)175Kndl/J
006234   B6.Cg-Tg(tetO-cre)1Jaw/J
005738   B6.FVB-Tg(tetO-EGFP,-Tgfbr2)8Mcle/J
021025   B6;129-Gt(ROSA)26Sortm1(rtTA*M2)Jae Col1a1tm1(tetO-cre)Haho/J
006911   B6;129-Gt(ROSA)26Sortm1(rtTA*M2)Jae Col1a1tm2(tetO-Pou5f1)Jae/J
011001   B6;129S4-Col1a1tm1(tetO-Pou5f1,-Klf4,-Sox2,-Myc)Hoch/J
016836   B6;129S4-Gt(ROSA)26Sortm1(rtTA*M2)Jae Col1a1tm7(tetO-HIST1H2BJ/GFP)Jae/J
012433   B6;C3-Tg(ACTA1-rtTA,tetO-cre)102Monk/J
002709   B6;C3-Tg(TettTALuc)1Dgs/J
023598   B6;C3-Tg(tetO-AIMP2)630Tmd/J
016841   B6;C3-Tg(tetO-TARDBP)12Vle/J
014650   B6;C3-Tg(tetO-TARDBP*)4Vle/J
012450   B6;D2-Tg(tetO-SNCA)1Cai/J
008344   B6;DBA-Tg(Fos-tTA,Fos-EGFP*)1Mmay Tg(tetO-lacZ,tTA*)1Mmay/J
024742   B6;DBA-Tg(tetO-GCaMP6s)2Niell/J
024088   B6;FVB-Tg(tetO-AML1/ETO)8Dzh/J
008082   B6;SJL-Tg(Tagln-tTA)1Mrab Tg(tetO-Mcpt1)1Mrab/J
010575   B6;SJL-Tg(tetO-Egfr*)2-9Jek/J
010577   B6;SJL-Tg(tetO-Erbb2*)8-4Jek/J
002621   B6;SJL-Tg(tetop-lacZ)2Mam/J
006004   B6C3-Tg(tetO-APPSwInd)885Dbo/Mmjax
016976   B6C3-Tg(tetO-SNCA*A53T)33Vle/J
018913   B6N.Cg-Tg(tetO-GFP,-lacZ)G3Rsp/J
006244   C.Cg-Tg(tetO-cre)1Jaw/J
017719   C3HeB/FeJ-Tg(tetO-TAg)1Efr/J
017955   C57BL/6-Tg(Gfap-rtTA,tetO-MAOB,-lacZ)1Jkan/J
005706   C57BL/6-Tg(tetO-CDK5R1/GFP)337Lht/J
006618   C57BL/6-Tg(tetO-COX8A/EYFP)1Ksn/J
017613   C57BL/6-Tg(tetO-Cdkn1b)1Scpr/J
013729   C57BL/6-Tg(tetO-EDN1,-lacZ)9Mhus/J
016260   C57BL/6-Tg(tetO-Fbxl21)38Jt/J
016179   C57BL/6-Tg(tetO-Fbxl21*)11Jt/J
010713   C57BL/6-Tg(tetO-GFP/tetX)5696Stl/J
013728   C57BL/6-Tg(tetO-NOS2,-lacZ)240iMhus/J
016181   C57BL/6-Tg(tetO-Nr1d1)1Schb/J
016581   C57BL/6J-Tg(tetO-Btrc*)1Jt/J
008278   C57BL/6J-Tg(tetO-Clock)1Jt/J
016580   C57BL/6J-Tg(tetO-Usf1)2Jt/J
021065   FVB(C)-Tg(tetO-Npc1/YFP)1Mps/J
017542   FVB-Tg(Myh6/tetO-ATP2B4)1Jmol/J
016571   FVB-Tg(Myh6/tetO-Gata6)2Jmol/J
014155   FVB-Tg(Myh6/tetO-Itpr1)22.3Jmol/J
014153   FVB-Tg(Myh6/tetO-Itpr2)3.11Jmol/J
014154   FVB-Tg(Myh6/tetO-Itpr2)4.9Jmol/J
012684   FVB-Tg(Myh6/tetO-POSTN)22.1Jmol/J
010580   FVB-Tg(Myh6/tetO-PRKCA*)1Jmk/J
013156   FVB-Tg(tetO-CDK5R1*)1Vln/J
013777   FVB-Tg(tetO-Cacna1g)1Jmol/J
013778   FVB-Tg(tetO-Cacnb2)1Jmol/J
013779   FVB-Tg(tetO-Cacnb2)2Jmol/J
013780   FVB-Tg(tetO-Cib1)1Jmol/J
010578   FVB-Tg(tetO-Dusp6)1Jmol/J
017333   FVB-Tg(tetO-Gnai2*,-lacZ)382Kndl/J
008685   FVB-Tg(tetO-Kdr*)4377.5Rwng/J
023397   FVB-Tg(tetO-Lmnb1)AF1Yfu/J
008695   FVB-Tg(tetO-MET)23Rwng/J
012387   FVB-Tg(tetO-Ppargc1a)1Dpk/J
012385   FVB-Tg(tetO-Ppargc1b)7Dpk/J
022979   FVB-Tg(tetO-Thbs4)17.7Jmol/J
006439   FVB-Tg(tetO/CMV-KRAS*G12C)9.1Msmi/J
019038   FVB.Cg-Tg(tetO-GLI1)10Rup/Mmjax
019039   FVB.Cg-Tg(tetO-KLF4)32831Rup/Mmjax
008244   FVB.Cg-Tg(tetO-cre)1Jaw/J
012459   FVB/N-Tg(Myh6*/tetO-Capn1)L2Gwd/J
005941   FVB/N-Tg(tetO-Aurkb,lacZ)41Kra/J
006202   FVB/N-Tg(tetO-BCR/ABL1)2Dgt/J
014547   FVB/N-Tg(tetO-Fasl)BDepa/J
019376   FVB/N-Tg(tetO-MYC)36aBop/J
022938   FVB/N-Tg(tetO-Wnt5a)17Rva/J
003315   FVB/N-Tg(tetORo1-lacZ)3Conk/J
005076   NOD.Cg-Tg(tetO-EGFP/FADD)1Doi/DoiJ
006999   STOCK Dbttm1Geh Tg(Cebpb-tTA)5Bjd Tg(tetO-DBT)A1Geh/J
011004   STOCK Gt(ROSA)26Sortm1(rtTA*M2)Jae Col1a1tm3(tetO-Pou5f1,-Sox2,-Klf4,-Myc)Jae/J
011011   STOCK Gt(ROSA)26Sortm1(rtTA*M2)Jae Col1a1tm4(tetO-Pou5f1,-Sox2,-Klf4,-Myc)Jae/J
011013   STOCK Gt(ROSA)26Sortm1(rtTA*M2)Jae Col1a1tm5(tetO-Pou5f1,-Klf4,-Myc)Jae/J
018999   STOCK Gt(ROSA)26Sortm1(tTA,tetO-Mir155)Fjsl/J
017596   STOCK Gt(ROSA)26Sortm1.1(rtTA,EGFP)Nagy Tg(SMN2)89Ahmb Smn1tm1Msd Tg(SMN2*delta7)4299Ahmb Tg(tetO-SMN2,-luc)#aAhmb/J
017597   STOCK Gt(ROSA)26Sortm1.1(rtTA,EGFP)Nagy Tg(SMN2)89Ahmb Smn1tm1Msd Tg(SMN2*delta7)4299Ahmb Tg(tetO-SMN2,-luc)#bAhmb/J
008755   STOCK Tg(Ins2-rtTA)2Efr Tg(teto-DTA)1Gfi/J
012477   STOCK Tg(Myh6*/tetO-GCaMP2)1Mik/J
016572   STOCK Tg(Myh6/tetO-Gata4)1Jmol/J
014544   STOCK Tg(tetO-ABL1*P242E*P249E)CPdav/J
014093   STOCK Tg(tetO-CHRM3*)1Blr/J
008790   STOCK Tg(tetO-DISC1*)1001Plet/J
008168   STOCK Tg(tetO-DTA)1Gfi/J
017755   STOCK Tg(tetO-GCAMP2)12iRyu/J
024509   STOCK Tg(tetO-Gata6)1Abl/J
016970   STOCK Tg(tetO-HCV)1Mlch/Mmjax
005104   STOCK Tg(tetO-HIST1H2BJ/GFP)47Efu/J
005699   STOCK Tg(tetO-Ipf1,EGFP)956.6Macd/J
005728   STOCK Tg(tetO-Ipf1,lacZ)958.1Macd/J
012441   STOCK Tg(tetO-LRRK2*G2019S)E3Cai/J
017918   STOCK Tg(tetO-MAML1*/EGFP)2Akar/J
017599   STOCK Tg(tetO-SMN2,-luc)#aAhmb/J
017600   STOCK Tg(tetO-SMN2,-luc)#bAhmb/J
012442   STOCK Tg(tetO-SNCA*A53T)E2Cai/J
006224   STOCK Tg(tetO-cre)1Jaw/J
017906   STOCK Tg(tetO-hop/EGFP,-COP4/mCherry)6Kftnk/J
012345   STOCK Tg(tetO-tdTomato,-Syp/EGFP*)1.1Luo/J
012449   STOCK Tg(teto-LRRK2)C7874Cai/J
View Strains carrying other alleles of tetO     (131 strains)

Additional Web Information

Tet Expression Systems

Visit the Alzheimer's Disease Mouse Model Resource site for helpful information on Alzheimer's Disease and research resources.

Phenotype

Phenotype Information

View Related Disease (OMIM) Terms

Related Disease (OMIM) Terms provided by MGI
- Characteristics of this human disease are associated with transgenes and other mutation types in the mouse.
Alzheimer Disease; AD
Frontotemporal Dementia; FTD
- Potential model based on transgenic expression of an ortholog of a human gene that is associated with this disease. Phenotypic similarity to the human disease has not been tested.
Parkinson Disease, Late-Onset; PD   (MAPT)
Parkinson-Dementia Syndrome   (MAPT)
Pick Disease of Brain   (MAPT)
Supranuclear Palsy, Progressive, 1; PSNP1   (MAPT)
View Mammalian Phenotype Terms

Mammalian Phenotype Terms provided by MGI
      assigned by genotype

The following phenotype relates to a compound genotype created using this strain.
Contact JAX® Services jaxservices@jax.org for customized breeding options.

Tg(Camk2a-tTA)1Mmay/0 Tg(tetO-MAPT*P301L)#Kha/0

        involves: 129/Sv * C57BL/6 * CBA * FVB/N
  • nervous system phenotype
  • abnormal dentate gyrus morphology
    • progressive atrophy of dentate granule cells   (MGI Ref ID J:185792)
  • hippocampal neuron degeneration
    • progressive atrophy of hippocampal pyramidal neurons   (MGI Ref ID J:185792)

Tg(Camk2a-tTA)1Mmay/0 Tg(tetO-MAPT*P301L)#Kha/0

        involves: FVB/N
  • behavior/neurological phenotype
  • abnormal gait
    • from about 9.5 months of age, the most severely affected mutants exhibit decreased ambulation   (MGI Ref ID J:102973)
  • abnormal spatial reference memory
    • mutants first exhibit impaired spatial reference memory at 2.5 months of age, showing a slightly reduced search bias for the target quadrant than controls in the Morris water maze   (MGI Ref ID J:102973)
    • spatial memory retention becomes more impaired with age, especially after 4 months of age, with the mean probe performance being equal to random swimming, indicating little or no retention of spatial memory   (MGI Ref ID J:102973)
    • mutants exhibit cognitive impairments in the acquisition phases of the Morris water maze, showing a longer mean distance to locate the hidden platform   (MGI Ref ID J:102973)
  • decreased exploration in new environment
    • reduction in exploration in open-field tests   (MGI Ref ID J:102973)
  • dystonia
    • develop dystonic posture with tail rigor at 9.5 months of age   (MGI Ref ID J:102973)
  • hunched posture
    • from about 9.5 months of age, the most severely affected mutants develop hunched posture with hindlimb dysfunction and tail rigor   (MGI Ref ID J:102973)
  • impaired coordination
    • mutants exhibit longer latencies to traverse a beam   (MGI Ref ID J:102973)
  • impaired swimming
    • mutants develop an age-dependent increase in the time taken to start swimming, however they are able to achieve comparable mean swim speeds during probe trials   (MGI Ref ID J:102973)
  • limb grasping
    • clasping and limb retraction when lifted by the tail   (MGI Ref ID J:102973)
  • growth/size/body phenotype
  • weight loss
    • from about 9.5 months of age, the most severely affected mutants exhibit decreased body weight   (MGI Ref ID J:102973)
  • nervous system phenotype
  • abnormal corticospinal tract morphology
    • atrophy of the dorsal corticospinal tracts accompanied by loss of neurofilament   (MGI Ref ID J:102973)
  • abnormal spinal cord morphology
    • spinal cords appear thinner, however, no decrease in motor neuron density is seen   (MGI Ref ID J:102973)
  • astrocytosis
    • reactive astrocytes in forebrains of 10 month old mutants   (MGI Ref ID J:102973)
  • decreased brain weight
    • 4-7% reduction in brain weight at 4 months of age   (MGI Ref ID J:102973)
  • forebrain atrophy
    • atrophy of the forebrain is seen by 5 months of age   (MGI Ref ID J:102973)
  • neurofibrillary tangles
    • age-dependent progression of tau processing that results in pathophysiological deposition of tau as mature tangles in the brain   (MGI Ref ID J:102973)
    • mutants exhibit age-dependent progression of neurofibrillary tangle formation, with tangles first appearing in the neocortex and then progressing into the hippocampus and limbic structures with increasing age   (MGI Ref ID J:102973)
    • neurofibrillary tangles develop in the hippocampus in a distinct pattern; mature tangles occur initially in CA1 pyramidal neurons, spread to CA2, and by 8.5 months of age include pyramidal neurons in CA2 and granular neurons of the dentate gyrus   (MGI Ref ID J:102973)
  • neuron degeneration
    • degeneration in the hippocampus and neocortex is seen in 10 month old mutants   (MGI Ref ID J:102973)
    • hippocampal neuron degeneration
      • massive neuronal loss, most apparent in the CA1 region of the hippocampus   (MGI Ref ID J:102973)
  • tau protein deposits
    • abnormal conformations of tau are present in the hippocampus and neocortex of 2.5-month old mutants   (MGI Ref ID J:102973)
  • muscle phenotype
  • dystonia
    • develop dystonic posture with tail rigor at 9.5 months of age   (MGI Ref ID J:102973)

Tg(Camk2a-tTA)1Mmay/0 Tg(tetO-MAPT*P301L)#Kha/0

        involves: 129S6/SvEvTac * FVB/N
  • behavior/neurological phenotype
  • abnormal anxiety-related response   (MGI Ref ID J:207366)
    • decreased anxiety-related response
      • amount of time spent in open arms of elevated plus maze is increased relative to nontransgenic mice at 6 and 10 months of age, but not 2 months   (MGI Ref ID J:207366)
      • higher ratio of time spent in open not closed arms relative to nontransgenic mice at 10 months of age, but not 2 or 6 months   (MGI Ref ID J:207366)
      • exploration of light chamber is increased relative to nontransgenic mice at 6 months of age, but not 2 or 10 months   (MGI Ref ID J:207366)
      • higher ratio of time spent in light not dark relative to nontransgenic miceat 10 months of age, but not 2 or 6 months   (MGI Ref ID J:207366)
    • increased anxiety-related response
      • decreased tendency to explore the center of the open field relative to nontransgenic mice   (MGI Ref ID J:207366)
  • hyperactivity
    • mice exhibit progressive hyperactivity in open field analysis and elevated plus maze   (MGI Ref ID J:207366)
    • total distance travelled in open field assay is increased relative to nontransgenic mice at 6 and 10 months of age, but not 2 months   (MGI Ref ID J:207366)
    • average speed is increased relative to nontransgenic mice at 6 and 10 months of age, but not 2 months   (MGI Ref ID J:207366)
    • total time spent immobile is increased relative to nontransgenic mice at 6 and 10 months of age, but not 2 months   (MGI Ref ID J:207366)
  • impaired contextual conditioning behavior
    • progressive decrease in percent of time spent freezing in response to unconditioned stimulus beginning at 2 months of age   (MGI Ref ID J:207366)
  • impaired cued conditioning behavior
    • progressive decrease in percent of time spent freezing in response to conditioned stimulus beginning at 6 months of age   (MGI Ref ID J:207366)
  • increased exploration in new environment   (MGI Ref ID J:207366)
  • nervous system phenotype
  • neurofibrillary tangles
    • neurofibrilliary tangles are observed by immunostaining in the CA1 region of the hippocampus beginning at 6 months of age and progressing to an extensive pathology by 11 months of age   (MGI Ref ID J:207366)
    • neurofibrilliary tangles are observed by immunostaining in the amygdala beginning at 2 months of age and progressing to an extensive pathology by 10 months of age   (MGI Ref ID J:207366)
  • tau protein deposits
    • tau burden increases with age in the amygdala and CA1 region of the hippocampus   (MGI Ref ID J:207366)

Tg(Camk2a-tTA)1Mmay/? Tg(tetO-MAPT*P301L)#Kha/?

        involves: 129S6/SvEvTac * FVB/N
  • nervous system phenotype
  • abnormal hippocampus CA1 region morphology
    • significant decrease in total numbers of CA1 hippocampal neurons   (MGI Ref ID J:99626)
    • CA1 neuron estimates were stabilized after brief (6- to 8-week) doxycycline treatment   (MGI Ref ID J:99626)
  • abnormal neuron morphology
    • the neuronal inclusions composed of a mass of straight tau filaments   (MGI Ref ID J:99626)
    • when treated with doxycycline at 2.5 month, the tau pathology ceased to progress   (MGI Ref ID J:99626)
    • decreased hippocampus pyramidal cell number
      • approximately 23% of CA1 pyramidal cells remaining at 8.5 months   (MGI Ref ID J:99626)
      • CA1 neuron estimates were stabilized after brief (6- to 8-week) doxycycline treatment   (MGI Ref ID J:99626)
  • decreased brain weight
    • a significant loss in brain weight by 5.5 months   (MGI Ref ID J:99626)
    • when treated with doxycycline during 5.5 to 10 months, the loss of brain weight was significantly protected   (MGI Ref ID J:99626)
  • forebrain atrophy
    • gross atrophy of the forebrain was evident in a 10-month-old mouse   (MGI Ref ID J:99626)
  • neurofibrillary tangles
    • develop argyrophilic tangle-like inclusions in the cortex by 4 months and in the hippocampal formation by 5.5 months   (MGI Ref ID J:99626)
    • when treated with doxycycline at 2.5 month, the tau pathology ceased to progress   (MGI Ref ID J:99626)
  • behavior/neurological phenotype
  • abnormal spatial learning
    • he retention of spatial memory examined by the Morris water maze were impaired as the mice aged   (MGI Ref ID J:99626)
    • deficit in spatial navigation was also seen in younger mice   (MGI Ref ID J:99626)
    • the performance improved when treated with doxycycline at 2.5 month-old or at 5.5 month-old   (MGI Ref ID J:99626)
View Research Applications

Research Applications
This mouse can be used to support research in many areas including:

Neurobiology Research
Alzheimer's Disease
      Tau (Mapt) mutants
      inducible models
Neurodegeneration
Tet Expression System
      tTA/rtTA Responsive Strains

Research Tools
Genetics Research
      Mutagenesis and Transgenesis
      Mutagenesis and Transgenesis: Tetop Tet System
Neurobiology Research
      Tetop Tet System

MAPT related

Neurobiology Research
Alzheimer's Disease
Parkinson's Disease

Genes & Alleles

Gene & Allele Information provided by MGI

 
Allele Symbol Tg(tetO-MAPT*P301L)#Kha
Allele Name transgene insertion, Karen Hsiao Ashe
Allele Type Transgenic (Inducible, Inserted expressed sequence)
Common Name(s) Tg(tetO-TauP301L)4510; rTg4510;
Strain of OriginFVB/N
Expressed Gene MAPT, microtubule-associated protein tau, human
Promoter tetO, tet operator,
Molecular Note The human four-repeat tau gene lacking the amino-terminal sequences (4R0N) containing the frontotemporal dementia-associated P301L mutation sequence was placed downstream of the tetracycline-responsive (TRE or tetO) promoter and inserted into the contextof the mouse prion protein gene (prnp) exons 2-3 transcribed but untranslated sequences. When mice are crossed with a line expressing a tTA transgene, Tg(Camk2a-tTA)1Mmay, these mice show the doxycycline sensitivity for transgene suppression. At leasttwo bitransgenic lines were established that can be suppressed with doxycycline. One bitransgenic mouse strain expressing approximately 13 units of tauP301L transgene was named rTg(tau P301L)4510 and was analyzed further. [MGI Ref ID J:99626]
 
 

Genotyping

Genotyping Information

Genotyping Protocols

B6 Tau strain, QPCR


Helpful Links

Genotyping resources and troubleshooting

References

References provided by MGI

Selected Reference(s)

Cook C; Dunmore JH; Murray ME; Scheffel K; Shukoor N; Tong J; Castanedes-Casey M; Phillips V; Rousseau L; Penuliar MS; Kurti A; Dickson DW; Petrucelli L; Fryer JD. 2014. Severe amygdala dysfunction in a MAPT transgenic mouse model of frontotemporal dementia. Neurobiol Aging 35(7):1769-77. [PubMed: 24503275]  [MGI Ref ID J:207366]

Liu L. 2012. Trans-Synaptic spread of Tau pathology In Vivo PLoS ONE 7(2):e31302.  [MGI Ref ID J:179960]

Santacruz K; Lewis J; Spires T; Paulson J; Kotilinek L; Ingelsson M; Guimaraes A; DeTure M; Ramsden M; McGowan E; Forster C; Yue M; Orne J; Janus C; Mariash A; Kuskowski M; Hyman B; Hutton M; Ashe KH. 2005. Tau suppression in a neurodegenerative mouse model improves memory function. Science 309(5733):476-81. [PubMed: 16020737]  [MGI Ref ID J:99626]

Additional References

Tg(tetO-MAPT*P301L)#Kha related

Abisambra JF; Jinwal UK; Blair LJ; O'Leary JC 3rd; Li Q; Brady S; Wang L; Guidi CE; Zhang B; Nordhues BA; Cockman M; Suntharalingham A; Li P; Jin Y; Atkins CA; Dickey CA. 2013. Tau accumulation activates the unfolded protein response by impairing endoplasmic reticulum-associated degradation. J Neurosci 33(22):9498-507. [PubMed: 23719816]  [MGI Ref ID J:198658]

Cheng J; Ji D. 2013. Rigid firing sequences undermine spatial memory codes in a neurodegenerative mouse model. Elife 2:e00647. [PubMed: 23805379]  [MGI Ref ID J:207802]

DuBoff B; Gotz J; Feany MB. 2012. Tau promotes neurodegeneration via DRP1 mislocalization in vivo. Neuron 75(4):618-32. [PubMed: 22920254]  [MGI Ref ID J:188334]

Han HJ; Allen CC; Buchovecky CM; Yetman MJ; Born HA; Marin MA; Rodgers SP; Song BJ; Lu HC; Justice MJ; Probst FJ; Jankowsky JL. 2012. Strain background influences neurotoxicity and behavioral abnormalities in mice expressing the tetracycline transactivator. J Neurosci 32(31):10574-86. [PubMed: 22855807]  [MGI Ref ID J:185792]

Harris JA; Koyama A; Maeda S; Ho K; Devidze N; Dubal DB; Yu GQ; Masliah E; Mucke L. 2012. Human P301L-mutant tau expression in mouse entorhinal-hippocampal network causes tau aggregation and presynaptic pathology but no cognitive deficits. PLoS One 7(9):e45881. [PubMed: 23029293]  [MGI Ref ID J:191974]

Khan UA; Liu L; Provenzano FA; Berman DE; Profaci CP; Sloan R; Mayeux R; Duff KE; Small SA. 2014. Molecular drivers and cortical spread of lateral entorhinal cortex dysfunction in preclinical Alzheimer's disease. Nat Neurosci 17(2):304-11. [PubMed: 24362760]  [MGI Ref ID J:208008]

Kopeikina KJ; Carlson GA; Pitstick R; Ludvigson AE; Peters A; Luebke JI; Koffie RM; Frosch MP; Hyman BT; Spires-Jones TL. 2011. Tau accumulation causes mitochondrial distribution deficits in neurons in a mouse model of tauopathy and in human Alzheimer's disease brain. Am J Pathol 179(4):2071-82. [PubMed: 21854751]  [MGI Ref ID J:176290]

Kopeikina KJ; Wegmann S; Pitstick R; Carlson GA; Bacskai BJ; Betensky RA; Hyman BT; Spires-Jones TL. 2013. Tau causes synapse loss without disrupting calcium homeostasis in the rTg4510 model of tauopathy. PLoS One 8(11):e80834. [PubMed: 24278327]  [MGI Ref ID J:209779]

Kuchibhotla KV; Wegmann S; Kopeikina KJ; Hawkes J; Rudinskiy N; Andermann ML; Spires-Jones TL; Bacskai BJ; Hyman BT. 2014. Neurofibrillary tangle-bearing neurons are functionally integrated in cortical circuits in vivo. Proc Natl Acad Sci U S A 111(1):510-4. [PubMed: 24368848]  [MGI Ref ID J:206375]

Larson ME; Sherman MA; Greimel S; Kuskowski M; Schneider JA; Bennett DA; Lesne SE. 2012. Soluble alpha-Synuclein Is a Novel Modulator of Alzheimer's Disease Pathophysiology. J Neurosci 32(30):10253-66. [PubMed: 22836259]  [MGI Ref ID J:186543]

Ljungberg MC; Ali YO; Zhu J; Wu CS; Oka K; Zhai RG; Lu HC. 2012. CREB-activity and nmnat2 transcription are down-regulated prior to neurodegeneration, while NMNAT2 over-expression is neuroprotective, in a mouse model of human tauopathy. Hum Mol Genet 21(2):251-67. [PubMed: 22027994]  [MGI Ref ID J:179018]

Nash KR; Lee DC; Hunt JB Jr; Morganti JM; Selenica ML; Moran P; Reid P; Brownlow M; Guang-Yu Yang C; Savalia M; Gemma C; Bickford PC; Gordon MN; Morgan D. 2013. Fractalkine overexpression suppresses tau pathology in a mouse model of tauopathy. Neurobiol Aging 34(6):1540-8. [PubMed: 23332170]  [MGI Ref ID J:203368]

Polydoro M; de Calignon A; Suarez-Calvet M; Sanchez L; Kay KR; Nicholls SB; Roe AD; Pitstick R; Carlson GA; Gomez-Isla T; Spires-Jones TL; Hyman BT. 2013. Reversal of Neurofibrillary Tangles and Tau-Associated Phenotype in the rTgTauEC Model of Early Alzheimer's Disease. J Neurosci 33(33):13300-11. [PubMed: 23946388]  [MGI Ref ID J:200903]

Pozueta J; Lefort R; Shelanski ML. 2013. Synaptic changes in Alzheimer's disease and its models. Neuroscience 251:51-65. [PubMed: 22687952]  [MGI Ref ID J:207068]

Ramsden M; Kotilinek L; Forster C; Paulson J; McGowan E; SantaCruz K; Guimaraes A; Yue M; Lewis J; Carlson G; Hutton M; Ashe KH. 2005. Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L). J Neurosci 25(46):10637-47. [PubMed: 16291936]  [MGI Ref ID J:102973]

Rocher AB; Crimins JL; Amatrudo JM; Kinson MS; Todd-Brown MA; Lewis J; Luebke JI. 2010. Structural and functional changes in tau mutant mice neurons are not linked to the presence of NFTs. Exp Neurol 223(2):385-93. [PubMed: 19665462]  [MGI Ref ID J:162373]

Vanderweyde T; Yu H; Varnum M; Liu-Yesucevitz L; Citro A; Ikezu T; Duff K; Wolozin B. 2012. Contrasting Pathology of the Stress Granule Proteins TIA-1 and G3BP in Tauopathies. J Neurosci 32(24):8270-83. [PubMed: 22699908]  [MGI Ref ID J:185575]

Yue M; Hanna A; Wilson J; Roder H; Janus C. 2011. Sex difference in pathology and memory decline in rTg4510 mouse model of tauopathy. Neurobiol Aging 32(4):590-603. [PubMed: 19427061]  [MGI Ref ID J:173738]

de Calignon A; Fox LM; Pitstick R; Carlson GA; Bacskai BJ; Spires-Jones TL; Hyman BT. 2010. Caspase activation precedes and leads to tangles. Nature 464(7292):1201-4. [PubMed: 20357768]  [MGI Ref ID J:159296]

de Calignon A; Polydoro M; Suarez-Calvet M; William C; Adamowicz DH; Kopeikina KJ; Pitstick R; Sahara N; Ashe KH; Carlson GA; Spires-Jones TL; Hyman BT. 2012. Propagation of tau pathology in a model of early Alzheimer's disease. Neuron 73(4):685-97. [PubMed: 22365544]  [MGI Ref ID J:182498]

Health & husbandry

Health & Colony Maintenance Information

Animal Health Reports

Room Number           AX18

Colony Maintenance

Breeding & HusbandryWhen maintaining a live colony, hemizygous mice may be bred to wildtype (non-carrier) mice from the colony or to FVB/NJ inbred mice (Stock No. 001800).
Mating SystemNoncarrier x Hemizygote         (Female x Male)   20-OCT-11
Hemizygote x Noncarrier         (Female x Male)   20-OCT-11
Diet Information LabDiet® 5K52/5K67

Pricing and Purchasing

Pricing, Supply Level & Notes, Controls


Pricing for USA, Canada and Mexico shipping destinations View International Pricing

Live Mice

Price per mouse (US dollars $)GenderGenotypes Provided
Individual Mouse $232.00Female or MaleHemizygous for Tg(tetO-MAPT*P301L)#Kha  
Price per Pair (US dollars $)Pair Genotype
$304.00Hemizygous for Tg(tetO-MAPT*P301L)#Kha x Noncarrier  
$304.00Noncarrier x Hemizygous for Tg(tetO-MAPT*P301L)#Kha  

Standard Supply

Repository-Live.
Repository-Live represents an exclusive set of over 1800 unique mouse models across a vast array of research areas. Breeding colonies provide mice for large and small orders and fluctuate in size depending on current research demand. If a strain is not immediately available, you will receive an estimated availability timeframe for your inquiry or order in 2-3 business days. Repository strains typically are delivered at 4 to 8 weeks of age. Requests for specific ages will be noted but not guaranteed and we do not accept age requests for breeder pairs. However, if cohorts of mice (5 or more of one gender) are needed at a specific age range for experiments, we will do our best to accommodate your age request.

Pricing for International shipping destinations View USA Canada and Mexico Pricing

Live Mice

Price per mouse (US dollars $)GenderGenotypes Provided
Individual Mouse $301.60Female or MaleHemizygous for Tg(tetO-MAPT*P301L)#Kha  
Price per Pair (US dollars $)Pair Genotype
$395.20Hemizygous for Tg(tetO-MAPT*P301L)#Kha x Noncarrier  
$395.20Noncarrier x Hemizygous for Tg(tetO-MAPT*P301L)#Kha  

Standard Supply

Repository-Live.
Repository-Live represents an exclusive set of over 1800 unique mouse models across a vast array of research areas. Breeding colonies provide mice for large and small orders and fluctuate in size depending on current research demand. If a strain is not immediately available, you will receive an estimated availability timeframe for your inquiry or order in 2-3 business days. Repository strains typically are delivered at 4 to 8 weeks of age. Requests for specific ages will be noted but not guaranteed and we do not accept age requests for breeder pairs. However, if cohorts of mice (5 or more of one gender) are needed at a specific age range for experiments, we will do our best to accommodate your age request.

View USA Canada and Mexico Pricing View International Pricing

Standard Supply

Repository-Live.
Repository-Live represents an exclusive set of over 1800 unique mouse models across a vast array of research areas. Breeding colonies provide mice for large and small orders and fluctuate in size depending on current research demand. If a strain is not immediately available, you will receive an estimated availability timeframe for your inquiry or order in 2-3 business days. Repository strains typically are delivered at 4 to 8 weeks of age. Requests for specific ages will be noted but not guaranteed and we do not accept age requests for breeder pairs. However, if cohorts of mice (5 or more of one gender) are needed at a specific age range for experiments, we will do our best to accommodate your age request.

Control Information

  Control
   Noncarrier
   001800 FVB/NJ
 
  Considerations for Choosing Controls
  Control Pricing Information for Genetically Engineered Mutant Strains.
 

Payment Terms and Conditions

Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.


See Terms of Use tab for General Terms and Conditions


The Jackson Laboratory's Genotype Promise

The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project.
Ordering Information
JAX® Mice
Surgical and Preconditioning Services
JAX® Services
Customer Services and Support
Tel: 1-800-422-6423 or 1-207-288-5845
Fax: 1-207-288-6150
Technical Support Email Form

Terms of Use

Terms of Use


General Terms and Conditions


For Licensing and Use Restrictions view the link(s) below:
- Use of MICE by companies or for-profit entities requires a license prior to shipping.

Contact information

General inquiries regarding Terms of Use

Contracts Administration

phone:207-288-6470

JAX® Mice, Products & Services Conditions of Use

"MICE" means mouse strains, their progeny derived by inbreeding or crossbreeding, unmodified derivatives from mouse strains or their progeny supplied by The Jackson Laboratory ("JACKSON"). "PRODUCTS" means biological materials supplied by JACKSON, and their derivatives. "RECIPIENT" means each recipient of MICE, PRODUCTS, or services provided by JACKSON including each institution, its employees and other researchers under its control. MICE or PRODUCTS shall not be: (i) used for any purpose other than the internal research, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services. Acceptance of MICE or PRODUCTS from JACKSON shall be deemed as agreement by RECIPIENT to these conditions, and departure from these conditions requires JACKSON's prior written authorization.

No Warranty

MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.

In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of mice, products or services, JACKSON will, at its option, provide credit or replacement for the mice or product received or the services provided.

No Liability

In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS or services from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.

MICE and PRODUCTS are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.

The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or services. In addition, special terms and conditions of sale of certain MICE, PRODUCTS or services may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and services by JACKSON, and by its licensees and distributors.

Acceptance of delivery of MICE, PRODUCTS or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or services by JACKSON.


(6.6)